Tonix Pharmaceuticals Presents Positive Data on TONMYA™ for Fibromyalgia at AAPM PainConnect

CHATHAM, N.J., March 3, 2026 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced today that a poster presentation on TONMYA™ (cyclobenzaprine HCl sublingual tablets), previously investigated as TNX-102 SL, will be presented at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, taking place March 5–8, 2026, in Salt Lake City, Utah. Source

TONMYA™ and Fibromyalgia Treatment

The poster, titled “Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia,” will be presented on March 6, 2026, at 4:55 PM ET. Source The presentation will be delivered by Errol Gould, PhD, Vice President, Medical Affairs of Tonix Pharma.

TONMYA™ is the first new treatment for fibromyalgia approved in over 15 years. Source It is a cyclobenzaprine HCl sublingual tablet designed for patients suffering from this chronic condition.

Tonix Pharmaceuticals Pipeline and Financial Position

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company with a focus on central nervous system (CNS) and immunology treatments. Source Beyond TONMYA™, the company markets Zembrace® SymTouch® and Tosymra® for acute migraine.

The company is too actively pursuing clinical trials to evaluate TONMYA’s potential in major depressive disorder and acute stress disorder. Additional CNS programs include TNX-2900, which is in Phase 2 development for Prader-Willi syndrome. Source Tonix is also developing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention.

As of December 31, 2025, Tonix reported approximately $208 million in cash with no debt, providing a cash runway expected to extend into the first quarter of 2027. Source The company reported net sales of $1.4 million for TONMYA™ from November 17 to December 31, 2026, supported by a field sales force of approximately 90 representatives and a patient access program. Source TONMYA™ wholesale acquisition costs are $1,860 for a 60-count prescription and $930 for a 30-count prescription. Source

A copy of the company’s presentation will be available on the Tonix website under the Presentations tab: https://ir.tonixpharma.com/presentations